
    
      Subjects will be randomized into 3 groups and will be followed for 6 months with 4 scheduled
      contacts per subjects. The immune response will be evaluated at days 0, 21 and 180 after
      vaccination. The safety evaluation will involve follow-up of solicited local and general
      signs and symptoms, unsolicited adverse events and serious adverse events.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    
  